GEN

Fluidigm and SABiosciences to Develop Pathway-Focused PCR Gene-Expression Panels

SABiosciences’ arrays will be validated for use on Fluidigm’s BioMark System and integrated fluidic circuits. Fluidigm and SABiosciences are teaming up to create over 100 pathway-focused ...
Nasdaq

Biomark X Offers Industry-Leading Advantages in Speed, Throughput, Flexibility and Cost

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health ...
Nasdaq

Regional CLIA-Certified Labs among Growing Number of Customers Expanding SARS-CoV-2 Testing with Fluidigm Technology

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive ...
Business Insider

GnomeDX Files for FDA Emergency Use Authorization for Rapid Turnaround Real-Time RT-PCR COVID-19 Test Utilizing the Fluidigm Biomark HD Platform

Test Intended to Expand Availability of COVID-19 Screening Resources in Central Ohio Workflow with Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Increasing Number of Labs Adopting ...
Business Wire

Kyoto University’s CiRA (Director, Dr. Yamanaka) Purchases Fluidigm BioMark™ System for Stem Cell Reprogramming Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation today announced that the Center for iPS Cell Research and Application (CiRA; Director Dr. Shinya Yamanaka) of Kyoto University’s ...